Diabetes Outcomes Trial Requirement Looks 'Increasingly Wise' – FDA’s Temple
FDA’s review of novel efficacy endpoints for diabetes therapies inevitably included discussion of the future of the cardiovascular outcomes study requirement for type 2 diabetes therapies; comments by FDA and EMA officials sure make it sound like the requirement isn’t going away any time soon.
You may also be interested in...
When US FDA adopted new outcomes standards for novel diabetes drugs in 2008, there were dire warnings that it would kill product development for the disease. When an advisory committee revisited the issue in 2018, however, there was almost unanimous agreement that the guidelines have been positive. Almost.
Endocrinologic and Metabolic Drugs Advisory Committee will reconsider 2008 guidance on evaluating CV risks in antidiabetic therapies at two-day meeting in October.
In an interview, Joseph Gulfo, former medtech industry CEO and vocal FDA critic, outlines his worldview and interest in pushing aggressively against increasing the FDA ‘body of law.’